Spark Investment Management LLC boosted its stake in China Cord Blood Corporation (NYSE:CO) by 273.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 114,800 shares of the medical research company’s stock after buying an additional 84,100 shares during the period. Spark Investment Management LLC’s holdings in China Cord Blood Corporation were worth $1,088,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC raised its stake in China Cord Blood Corporation by 5.5% in the second quarter. Acadian Asset Management LLC now owns 622,995 shares of the medical research company’s stock valued at $5,904,000 after buying an additional 32,592 shares in the last quarter. Parametrica Management Ltd purchased a new stake in China Cord Blood Corporation during the second quarter valued at about $149,000. Renaissance Technologies LLC raised its stake in China Cord Blood Corporation by 6.5% in the first quarter. Renaissance Technologies LLC now owns 859,500 shares of the medical research company’s stock valued at $5,724,000 after buying an additional 52,700 shares in the last quarter. Financial Counselors Inc. raised its stake in China Cord Blood Corporation by 6.0% in the first quarter. Financial Counselors Inc. now owns 92,056 shares of the medical research company’s stock valued at $613,000 after buying an additional 5,226 shares in the last quarter. Finally, Brandes Investment Partners LP purchased a new stake in China Cord Blood Corporation during the first quarter valued at about $263,000. 18.41% of the stock is owned by institutional investors.

China Cord Blood Corporation (NYSE:CO) opened at 11.95 on Thursday. The company has a market capitalization of $1.44 billion, a P/E ratio of 50.42 and a beta of 0.94. The firm has a 50-day moving average price of $10.48 and a 200 day moving average price of $7.81. China Cord Blood Corporation has a 1-year low of $4.27 and a 1-year high of $12.44.

China Cord Blood Corporation (NYSE:CO) last posted its quarterly earnings data on Wednesday, June 21st. The medical research company reported $0.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.02. The business had revenue of $29.35 million during the quarter. China Cord Blood Corporation had a return on equity of 7.05% and a net margin of 16.46%. On average, equities analysts predict that China Cord Blood Corporation will post $0.15 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Spark Investment Management LLC Has $1.09 Million Stake in China Cord Blood Corporation (NYSE:CO)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/spark-investment-management-llc-has-1-09-million-stake-in-china-cord-blood-corporation-nyseco/1468061.html.

Separately, BidaskClub raised shares of China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 1st.

China Cord Blood Corporation Company Profile

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Want to see what other hedge funds are holding CO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Cord Blood Corporation (NYSE:CO).

Institutional Ownership by Quarter for China Cord Blood Corporation (NYSE:CO)

Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.